Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (367)	5/29/2003 12:16:32 PM
From: nigel bates	Read Replies (1) \| Respond to of 625

White said he expects Humira could be a "multibillion dollar" product. Now if he could just show a little gratitude to the company that came up with it...

To: tuck who wrote (367)	5/30/2003 10:11:39 AM
From: nigel bates	Read Replies (1) \| Respond to of 625

CAMBRIDGE, England, May 30 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (Nasdaq: CATG - News; LSE: CAT - News) today acknowledges the announcement made by Abbott Laboratories at a meeting held yesterday for investors and financial analysts. Abbott announced that it has raised its 2003 sales expectations for HUMIRA(TM) from more than $200 million to $250 million. Abbott also announced development progress with ABT-874 (formerly J695), discussing promising Phase II Crohn's disease data for ABT-874 and plans for a Phase II study in multiple sclerosis in the first half of 2004. HUMIRA was isolated and optimised by CAT in collaboration with Abbott, and CAT will receive royalties on the sales of HUMIRA. ABT-874 was also isolated and optimised by CAT and Abbott, and was licensed by CAT to Abbott under the same 1995 agreement between CAT and Knoll Aktiengesellschaft (now a subsidiary of Abbott Laboratories). CAT receives development milestone payments and will receive royalties on sales of ABT-874...